Data from Sequenta’s LymphoSIGHTTM Platform for the Detection of Minimal Residual Disease Presented at the European Hematology Association Meeting

Published: Jun 15, 2012

SAN FRANCISCO--(BUSINESS WIRE)--Sequenta, Inc. announced today that data demonstrating the power of its DNA sequencing-based LymphoSIGHTTM platform for the detection of Minimal Residual Disease (MRD) was presented during the European Hematology Association (EHA) meeting in Amsterdam June 15.

Back to news